Insurance Companies Commit to Reducing Delays in Healthcare Approvals

Major insurance providers in the U.S. have pledged to speed up prior authorization processes, aiming to reduce delays and improve patient access to care. However, experts remain cautious about the extent of these reforms.
In an effort to address lengthy delays in healthcare approvals, several major insurance providers in the United States have announced plans to expedite the prior authorization process. Previously, obtaining approval from insurance companies before procedures or treatments could be a significant hurdle, leading to frustration among patients and healthcare providers alike.
U.S. Health and Human Services Secretary Robert F. Kennedy Jr. highlighted that leading insurers, including Blue Cross Blue Shield Association, Cigna, Elevance Health, GuideWell, Humana, Kaiser Permanente, and UnitedHealthcare, have agreed to implement measures aimed at reforming how they handle prior authorizations. These measures are expected to impact private insurance plans, Medicare Advantage, and Medicaid.
According to recent surveys from the health policy group KFF, approximately one in six insured adults in the U.S. have experienced difficulties with prior authorization processes. The industry group AHIP estimates these changes could benefit up to 257 million Americans.
However, experts like Dr. Adam Gaffney from Harvard Medical School remain cautiously optimistic. He points out that previous promises of reform in 2018 and 2023 did not lead to substantial changes, and suggests that the current efforts may only produce incremental improvements. Dr. Mehmet Oz, head of the Centers for Medicare & Medicaid Services, emphasizes that public frustration and recent violent incidents involving insurance executives highlight the urgency for meaningful reform.
Starting in the upcoming year, insurers will be required to honor prior authorizations from previous plans for at least 90 days if a patient switches insurance providers. Additionally, plans will need to provide clearer reasons for care denials and guide patients through the appeals process. By 2027, the goal is for at least 80% of electronic prior authorization requests to be processed in real-time and to simplify the online submission process.
Some insurers may also reduce the number of procedures requiring prior approval, with specific examples yet to be disclosed. CMS aims to eliminate prior authorization requirements for common procedures such as colonoscopies, cataract surgeries, and childbirth, and to improve access to services like physical therapy, diagnostic imaging, and outpatient surgeries.
Despite these commitments, skepticism persists among health care experts, who argue that deeper, more fundamental reforms are necessary to truly dismantle the barriers created by insurance policies.
For more insights, Harvard Health provides details on prior authorization processes. Source: https://medicalxpress.com/news/2025-06-delays-health.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Blood Test for Insulin Resistance May Help Predict Early Alzheimer's Cognitive Decline
A simple blood test measuring insulin resistance using the TyG index may predict the rate of cognitive decline in early Alzheimer's disease, opening new possibilities for early intervention and personalized treatment.
Global Bioethics Training: Successes and Challenges in Building Ethical Research Capacity
A pioneering study highlights the achievements and hurdles in international bioethics training programs supported by NIH, emphasizing their importance in strengthening ethical research capacity in low- and middle-income countries.
Innovative Immunotherapy Approach for Alzheimer's Inspired by Cancer Treatments
Discover how cutting-edge immunotherapy technology, originally developed for cancer, is now being adapted to target Alzheimer's disease by engineering immune cells that recognize toxic protein accumulations in the brain.
Rizatriptan Ineffective Compared to Placebo in Early Treatment of Vestibular Migraine
A recent clinical trial reveals that rizatriptan is no more effective than placebo in alleviating vertigo and other vestibular migraine symptoms within the first hour, challenging its routine use for this condition.



